Laboratory Corporation of America Holdings (LabCorp) has been garnering attention due to a series of
market activities and
financial movements. Spearheaded by Speece Thorson Capital Group Inc's decision to trim its holdings, other investors such as Sunpointe LLC, and Bridgewater Associates LP followed suit. On a positive note, the company's Q2 results look robust, and the acquisition of Sequenom rolled out promising prospects. A quarterly
dividend was declared, adding to the momentum of investors' returns. Despite some concerns over LabCorp's valuation, it announced the winning bid for select assets of Invitae and the acquisition of BioReference Health’s
Diagnostics assets. It reported mixed Q4 and Full Year 2023 results and unveiled improved 2024 EPS outlooks driven by
revenue surpassing expectations. Furthermore, LabCorp announced expansions within its oncology
portfolio, boosted its diagnostic capabilities, and secured a partnership with Hawthorne Effect, bringing clinical trials directly to patients. The company's
shareholders saw a 67% increase over five years, and those holding stock will soon be cashing in on dividends. However, there were also insider sales and underperformance compared to competitors on some trading days.
Laboratory Corporation of America Holdings LH News Analytics from Thu, 27 Jul 2023 07:00:00 GMT to Sun, 16 Jun 2024 17:03:00 GMT -
Rating 7
- Innovation 8
- Information 7
- Rumor 6
